Doxycycline

別名：Vibramycin, Doxytetracycline, Doxiciclina, Doxycyclinum

製品コード：S5159 純度：97%

Doxycycline（Vibramycin、Doxytetracycline、Doxiciclina、Doxycyclinum）は、細菌や原虫によって引き起こされる多くの種類の感染症の治療に使用される抗生物質です。Doxycyclineは非特異的なマトリックスメタロプロテイナーゼ（MMP）阻害剤でもあります。

CAS No. 564-25-0

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
25mg	JPY 22000	国内在庫あり
1g	JPY 55500	国内在庫あり

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（67）

質量管理及び製品安全説明書

現在のバッチを見る： 純度：>97%

Doxycycline関連製品

関連製品	Puromycin Dihydrochloride Staurosporine (STS) Cyclosporin A Oligomycin A (MCH 32) Nigericin sodium salt Geldanamycin (NSC 122750) Honokiol Streptozotocin (STZ) Sodium Monensin (NSC 343257) Hygromycin B Cephalomannine Pirarubicin Embelin 10-Deacetylbaccatin-III Roxithromycin Fumagillin	もっと見る
関連化合物ライブラリー	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	もっと見る

Antineoplastic and Immunosuppressive Antibiotics阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
vascular endothelial cells	Antibacterial assay	25 ug/ml	72 hrs	Antibacterial activity against Rickettsia prowazekii str. Breinl infected in CD rat primary pulmonary vascular endothelial cells assessed as bacterial shape change at 25 ug/ml measured 72 hrs post infection by Hoechst 33258/phalloidin staining based fluor	28089350
Hep2	Anti-Chlamydial assay	1 ug/ml	8 hrs	Anti-Chlamydial activity against Chlamydia trachomatis Serovar LGV-L2 infected in Hep2 cells assessed as reduction in size and number of chlamydial inclusion at 1 ug/ml treated at 8 hrs post-infection and 24 hrs later re-infecting fresh Hep2 cells monolay	32227948
SW1353	Function assay	50 uM		Inhibition of IL-1-beta-induced MMP13 production in human SW1353 cells at 50 uM	17267227
Neuro2a	Function assay	1 uM		Decrease in 7-DHC levels in Dhcr7-deficient mouse Neuro2a cells at 1 uM by LC-MS/GC-MS analysis	26789657
Staphylococcus aureus 2 planktonic cells	Bactericidal assay		24 hrs	Bactericidal activity against methicillin-resistant Staphylococcus aureus 2 planktonic cells after 24 hrs by calgary biofilm device method, MBC=2μM.	29638121
K562	Cytotoxicity assay		72 hrs	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50=15μM.	19482476
K562	Cytotoxicity assay		72 hrs	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50=15μM.	19926173
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50=20μM.	19482476
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50=20μM.	19926173
THP1	Cytotoxicity assay		72 hrs	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry, IC50=20μM.	19748781
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50=20μM.	21741131
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50=20μM.	22889559
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50=20μM.	21852132
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50=20μM.	24946216
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay, CC50=20μM.	25791675
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay, CC50=20μM.	25282267
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay, CC50=20μM.	27155463
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay, CC50=20μM.	27654395
K-12 BW25113	Bactericidal assay		24 hrs	Bactericidal activity against yafQ gene-deficient Escherichia coli K-12 BW25113 biofilm assessed as log reduction of viable cells after 24 hrs	19307375
K-12 BW25113	Bactericidal assay		24 hrs	Bactericidal activity against Escherichia coli K-12 BW25113 biofilm harboring pCA24N ptac::yafQ plasmid assessed as log reduction of viable cells after 24 hrs pretreated with 5 uM of IPTG for 4 hrs	19307375
THP1	Function assay			Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum, IC50=3.1μM.	19748781
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
skeletal myoblast cells	Cytotoxicity assay			DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells, IC50=14.49μM.	ChEMBL
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明	Doxycycline（Vibramycin、Doxytetracycline、Doxiciclina、Doxycyclinum）は、細菌や原虫によって引き起こされる多くの種類の感染症の治療に使用される抗生物質です。Doxycyclineは非特異的なマトリックスメタロプロテイナーゼ（MMP）阻害剤でもあります。

In Vitro
In vitro	100 ng/mL-5 µg/mL Doxycycline can significantly alter the metabolic profile of the cell, as well as reduce the proliferative rate, though the effect size depends upon the particular cell line used. This compound arrests cells in G1-S phase of the cell cycle in PANC-1 cells and induces the expression of p53 and its downstream target p21. It down-regulates antiapoptotic genes and induces proapoptotic genes. This chemical also induces apoptosis through a Fas/Fas-ligand dependent pathway in Jurkat T lymphocytes.
細胞実験	細胞株	U87 astrocytoma cells, lung cancer cell lines H157 and H1437, LNCaP prostate cancer and HeLa cervical cancer cell lines
	濃度	100 ng/mL, 1 µg/mL
	反応時間	24, 72, and 96 hours
	実験の流れ	Cells are seeded in 6 well plates at 50,000 cells per well and treated with Doxycycline (100 ng/mL, 1 µg/mL, or vehicle control). Cells are counted 24, 72, and 96 hours after plating using a particle counter.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	AKT / BCL6 / Cyclin E / HDAC2 / HDAC3 / NEMO / TYK2 / RIPK1 HSP70 / HSP90 pATM / ATM		26142707
	Immunofluorescence	E-cadherin / Vimentin		29285218

In Vivo
In Vivo	Doxycycline successfully reduces tumor growth in vivo (inhibited pancreatic cancer cell growth).
動物実験	動物モデル	Male nu/nu mice
	投与量	35 mg/pellet
	投与経路	s.c.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2026-03-20)
NCT07485010	NOT_YET_RECRUITING	Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease	The University of Queensland	2027-04	PHASE2
NCT07704957	NOT_YET_RECRUITING	Chlamydia Females; Gonorrhea Female; Syphilis Female; Adherence; Prophylaxis; Prevention	Tulane University	2027-01-01	PHASE4
NCT07488949	RECRUITING	Chronic Endometritis	Fang Wang	2024-04-09
NCT07164131	RECRUITING	Community-acquired Pneumonia	Mayo Clinic	2025-09-15	PHASE4
NCT05473520	RECRUITING	Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)	National University Hospital, Singapore	2023-05-24	PHASE3
NCT07658976	NOT_YET_RECRUITING	HIV Infection; Sexually Transmitted Infection	HIV Prevention Trials Network	2026-09-01	PHASE3

参考
https://pubmed.ncbi.nlm.nih.gov/23741339/ https://pubmed.ncbi.nlm.nih.gov/19846942/

参考

https://pubmed.ncbi.nlm.nih.gov/23741339/
https://pubmed.ncbi.nlm.nih.gov/19846942/

化学情報

分子量	444.43	化学式	C₂₂H₂₄N₂O₈
CAS No.	564-25-0	SDF	Download Doxycycline SDFをダウンロードする
Smiles	CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 89 mg/mL ( (200.25 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo Batch: Add solvents to the product individually and in order.				投与溶液組成計算機
Clear solution	1%DMSO 1 1%PEG300 2 98%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.060mg/ml (0.14mM)	Taking the 1 mL working solution as an example, add 10 μL of 6mg/ml clarified DMSO stock solution to 10 μL of PEG300, mix evenly to clarify it; add 980 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.100mg/ml (2.48mM)	Taking the 1 mL working solution as an example, add 50 μL of 22 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	3.250mg/ml (7.31mM)	Taking the 1 mL working solution as an example, add 50 μL of 65 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):